glp-1 gip muscle preservation therapies 2025 Therapy Part 1: Setting Realistic Weight Loss Expectations – Sarah Hormachea Weight Reduction with GLP-1 Agonists

Tatsumi, R., Sheehan, S

This is not unique to Belmar's formulation

Colhoun, G.R

Figure 1 illustrates schematically the formulations that have entered clinical development today

Around the same time, I think you remember that all of pharma was interested in obesity in the early 90s, everyone wanted to do diabetes as well as obesity, but they were separate teams and they all wanted to do small molecules, but it just happens to be so that the best idea we could find at that time was actually GLP-1, because we actually had clinical data relatively early that GLP-1 was a really good candidate as a treatment for diabetes because of the glucose sensitivity of the actions